CDIO investor deck: CMS $854/test rate set; Atlas coverage; Dr. Lal PathLabs India deal; lab scale-up

Cardio Diagnostics Holdings, Inc.

CMS final payment rate of $854 per test set (Dec 2025) for both Epi+Gen CHD (0439U) and PrecisionCHD (0440U) CPT codes.
Atlas Healthcare Physicians began in-network coverage with prior authorization (June 2026); out-of-network billing launched July 2026.
Dr. Lal PathLabs (290+ labs, 300+ pathologists) to offer PrecisionCHD in India; Aimil Ltd partnership extends distribution network.
Company-owned CLIA lab now processing tests in-house, cutting initial COGS ~30%; turnaround time 7-10 business days.
Combined US TAM ~$175B: 146M eligible for Epi+Gen CHD risk test, 60M for PrecisionCHD diagnostic; 40% gross margin target at scale.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.